<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28903775</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>06</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1475-2840</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Sep</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cardiovascular diabetology</Title>
          <ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.</ArticleTitle>
        <Pagination>
          <StartPage>113</StartPage>
          <MedlinePgn>113</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">113</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12933-017-0595-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial in patients with type 2 diabetes mellitus (T2D) at high risk of cardiovascular (CV) disease, saxagliptin did not increase the risk for major CV adverse events. However, there was an unexpected imbalance in events of hospitalization for heart failure (hHF), one of six components of the secondary CV composite endpoint, with a greater number of events observed with saxagliptin. Here, we examined findings from nonclinical safety and clinical pharmacology studies of saxagliptin with the aim of identifying any potential signals of myocardial injury.</AbstractText>
          <AbstractText Label="METHODS">In vitro and in vivo (rat, dog, monkey) safety pharmacology and toxicology studies evaluating the potential effects of saxagliptin and its major active metabolite, 5-hydroxy saxagliptin, on the CV system are reviewed. In addition, results from saxagliptin clinical studies are discussed: one randomized, 2-period, double-blind, placebo-controlled single-ascending-dose study (up to 100 mg); one randomized, double-blind, placebo-controlled, sequential, multiple-ascending-high-dose study (up to 400 mg/day for 14 days); and one randomized, double-blind, 4-period, 4-treatment, cross-over thorough QTc study (up to 40 mg/day for 4 days) in healthy volunteers; as well as one randomized, placebo-controlled, sequential multiple-ascending-dose study in patients with T2D (up to 50 mg/day for 14 days).</AbstractText>
          <AbstractText Label="RESULTS">Neither saxagliptin nor 5-hydroxy saxagliptin affected ligand binding to receptors and ion channels (e.g. potassium channels) or action potential duration in in vitro studies. In animal toxicology studies, no changes in the cardiac conduction system, blood pressure, heart rate, contractility, heart weight, or heart histopathology were observed. In healthy participants and patients with T2D, there were no findings suggestive of myocyte injury or fluid overload. Serum chemistry abnormalities indicative of cardiac injury, nonspecific muscle damage, or fluid homeostasis changes were infrequent and balanced across treatment groups. There were no QTc changes associated with saxagliptin. No treatment-emergent adverse events suggestive of heart failure or myocardial damage were reported.</AbstractText>
          <AbstractText Label="CONCLUSIONS">The saxagliptin nonclinical and clinical pharmacology programs did not identify evidence of myocardial injury and/or CV harm that may have predicted or may explain the unexpected imbalance in the rate of hHF observed in SAVOR.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pollack</LastName>
            <ForeName>Pia S</ForeName>
            <Initials>PS</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, 1 MedImmune Way, Gaithersburg, MD, 20878, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chadwick</LastName>
            <ForeName>Kristina D</ForeName>
            <Initials>KD</Initials>
            <AffiliationInfo>
              <Affiliation>Bristol-Myers Squibb, New Brunswick, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>David M</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Billger</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, Gothenburg, Mölndal, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirshberg</LastName>
            <ForeName>Boaz</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>MedImmune, Gaithersburg, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iqbal</LastName>
            <ForeName>Nayyar</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, 1 MedImmune Way, Gaithersburg, MD, 20878, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boulton</LastName>
            <ForeName>David W</ForeName>
            <Initials>DW</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, 1 MedImmune Way, Gaithersburg, MD, 20878, USA. david.boulton2@astrazeneca.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>09</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cardiovasc Diabetol</MedlineTA>
        <NlmUniqueID>101147637</NlmUniqueID>
        <ISSNLinking>1475-2840</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054715">Cardiotoxins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9GB927LAJW</RegistryNumber>
          <NameOfSubstance UI="C502994">saxagliptin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PJY633525U</RegistryNumber>
          <NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054715" MajorTopicYN="N">Cardiotoxins</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Diabetes mellitus</Keyword>
        <Keyword MajorTopicYN="Y">Heart failure</Keyword>
        <Keyword MajorTopicYN="Y">Pharmacology</Keyword>
        <Keyword MajorTopicYN="Y">Saxagliptin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28903775</ArticleId>
        <ArticleId IdType="pmc">PMC5598064</ArticleId>
        <ArticleId IdType="doi">10.1186/s12933-017-0595-6</ArticleId>
        <ArticleId IdType="pii">10.1186/s12933-017-0595-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, et al.  Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:5025–5037. doi: 10.1021/jm050261p.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm050261p</ArticleId>
            <ArticleId IdType="pubmed">16033281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang A, Dorso C, Kopcho L, Locke G, Langish R, Harstad E, et al.  Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol. 2012;12:2. doi: 10.1186/1471-2210-12-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2210-12-2</ArticleId>
            <ArticleId IdType="pmc">PMC3373380</ArticleId>
            <ArticleId IdType="pubmed">22475049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onglyza® US prescribing information. 2017. https://www.azpicentral.com/onglyza/pi_onglyza.pdf#page=1. Accessed 4 Sep 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Hirshberg B, Parker A, Edelberg H, Donovan M, Iqbal N. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2014;30:556–569. doi: 10.1002/dmrr.2502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dmrr.2502</ArticleId>
            <ArticleId IdType="pubmed">24376173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Center for Drug Evaluation and Research. 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 13 Apr 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326. doi: 10.1056/NEJMoa1307684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1307684</ArticleId>
            <ArticleId IdType="pubmed">23992601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol. 2015;14:129. doi: 10.1186/s12933-015-0294-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12933-015-0294-0</ArticleId>
            <ArticleId IdType="pmc">PMC4587723</ArticleId>
            <ArticleId IdType="pubmed">26415691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al.  Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary. Endocr Pract. 2017;23:207–238. doi: 10.4158/EP161682.CS.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4158/EP161682.CS</ArticleId>
            <ArticleId IdType="pubmed">28095040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avelox® US prescribing information. 2016. https://www.merck.com/product/usa/pi_circulars/a/avelox/avelox_pi.pdf. Accessed 4 Sept 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Desai M, Li L, Desta Z, Malik M, Flockhart D. Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol. 2003;55:511–517. doi: 10.1046/j.1365-2125.2003.01791.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2125.2003.01791.x</ArticleId>
            <ArticleId IdType="pmc">PMC1884246</ArticleId>
            <ArticleId IdType="pubmed">12814443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Billger M, Chadwick KD, Bergholm AM: Cardiovascular studies in mouse, rat, dog and monkey show no clinically relevant effects of the DPPIV inhibitor saxagliptin. In: 51st Congress of the European Societies of Toxicology: September 13–16 2015; Porto, Portugal; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Connelly KA, Advani A, Zhang Y, Advani SL, Kabir G, Abadeh A, et al.  Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: role of stromal cell-derived factor-1alpha. J Diabetes. 2016;8:63–75. doi: 10.1111/1753-0407.12258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1753-0407.12258</ArticleId>
            <ArticleId IdType="pubmed">25565455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikeda J, Kimoto N, Kitayama T, Kunori S. Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats. J Pharmacol Sci. 2016;132:65–70. doi: 10.1016/j.jphs.2016.08.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jphs.2016.08.008</ArticleId>
            <ArticleId IdType="pubmed">27666017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomez N, Touihri K, Matheeussen V, Mendes Da Costa A, Mahmoudabady M, Mathieu M, et al.  Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012;14:14–21. doi: 10.1093/eurjhf/hfr146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurjhf/hfr146</ArticleId>
            <ArticleId IdType="pubmed">22045924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S, Chattipakorn N. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol. 2013;167:451–457. doi: 10.1016/j.ijcard.2012.01.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijcard.2012.01.011</ArticleId>
            <ArticleId IdType="pubmed">22285447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi A, Asakura M, Ito S, Min KD, Shindo K, Yan Y, et al.  Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. Am J Physiol Heart Circ Physiol. 2013;304:H1361–H1369. doi: 10.1152/ajpheart.00454.2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpheart.00454.2012</ArticleId>
            <ArticleId IdType="pubmed">23504176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiemstra JA, Lee DI, Chakir K, Gutierrez-Aguilar M, Marshall KD, Zgoda PJ, et al.  Saxagliptin and tadalafil differentially alter cyclic guanosine monophosphate (cGMP) signaling and left ventricular function in aortic-banded mini-swine. J Am Heart Assoc. 2016;5:e003277. doi: 10.1161/JAHA.116.003277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/JAHA.116.003277</ArticleId>
            <ArticleId IdType="pmc">PMC4843537</ArticleId>
            <ArticleId IdType="pubmed">27098966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamagishi Si, Fukami K, Matsui T. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc Diabetol. 2015;14:2. doi: 10.1186/s12933-015-0176-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12933-015-0176-5</ArticleId>
            <ArticleId IdType="pmc">PMC4298871</ArticleId>
            <ArticleId IdType="pubmed">25582643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota Y, Miyamoto M, Takagi G, Ikeda T, Kirinoki-Ichikawa S, Tanaka K, et al.  The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012;27:1364–1370. doi: 10.3346/jkms.2012.27.11.1364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3346/jkms.2012.27.11.1364</ArticleId>
            <ArticleId IdType="pmc">PMC3492672</ArticleId>
            <ArticleId IdType="pubmed">23166419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ida S, Murata K, Betou K, Kobayashi C, Ishihara Y, Imataka K, et al.  Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study. Cardiovasc Diabetol. 2016;15:153. doi: 10.1186/s12933-016-0468-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12933-016-0468-4</ArticleId>
            <ArticleId IdType="pmc">PMC5096292</ArticleId>
            <ArticleId IdType="pubmed">27809903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, et al.  Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:83. doi: 10.1186/s12933-015-0242-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12933-015-0242-z</ArticleId>
            <ArticleId IdType="pmc">PMC4473835</ArticleId>
            <ArticleId IdType="pubmed">26084668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavender MA, Scirica BM, Raz I, Gabriel Steg P, McGuire DK, Leiter LA, et al.  Cardiovascular outcomes of patients in SAVOR-TIMI 53 by baseline hemoglobin A1c. Am J Med. 2016;129:340.e341–340.e348. doi: 10.1016/j.amjmed.2015.09.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjmed.2015.09.022</ArticleId>
            <ArticleId IdType="pubmed">26524706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al.  Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–1588. doi: 10.1161/CIRCULATIONAHA.114.010389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.114.010389</ArticleId>
            <ArticleId IdType="pubmed">25189213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scirica BM, Bhatt DL, Braunwald E, et al.  Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1:989–998. doi: 10.1001/jamacardio.2016.3030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamacardio.2016.3030</ArticleId>
            <ArticleId IdType="pubmed">27681000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iqbal N, Parker A, Frederich R, Donovan M, Hirshberg B. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol. 2014;13:33. doi: 10.1186/1475-2840-13-33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1475-2840-13-33</ArticleId>
            <ArticleId IdType="pmc">PMC3918110</ArticleId>
            <ArticleId IdType="pubmed">24490835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu AZ, Johnston SS, Ghannam A, Tsai K, Cappell K, Fowler R, et al.  Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study. Diabetes Care. 2016;39:726–734. doi: 10.2337/dc15-0764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc15-0764</ArticleId>
            <ArticleId IdType="pubmed">26740636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toh S, Hampp C, Reichman ME, Graham DJ, Balakrishnan S, Pucino F, et al.  Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med. 2016;164:705–714. doi: 10.7326/M15-2568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/M15-2568</ArticleId>
            <ArticleId IdType="pmc">PMC5178978</ArticleId>
            <ArticleId IdType="pubmed">27110660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang C-H, Chang Y-C, Lin J-W, Caffrey JL, Wu L-C, Lai M-S, et al.  No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan. Int J Cardiol. 2016;220:14–20. doi: 10.1016/j.ijcard.2016.06.125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijcard.2016.06.125</ArticleId>
            <ArticleId IdType="pubmed">27389437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fadini GP, Saragoni S, Russo P, Degli Esposti L, Vigili de Kreutzenberg S, Melazzini M, et al.  Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: results from the OsMed Health-DB registry. Diabetes Obes Metab. 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28432754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avogaro A, Fadini GP, Sesti G, Bonora E, Del Prato S. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol. 2016;15:111. doi: 10.1186/s12933-016-0431-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12933-016-0431-4</ArticleId>
            <ArticleId IdType="pmc">PMC4982334</ArticleId>
            <ArticleId IdType="pubmed">27514514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al.  Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242. doi: 10.1056/NEJMoa1501352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1501352</ArticleId>
            <ArticleId IdType="pubmed">26052984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335. doi: 10.1056/NEJMoa1305889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1305889</ArticleId>
            <ArticleId IdType="pubmed">23992602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zannad F, Cannon C, Cushman WC, Bakris G, Menon V, Perez A, et al.  Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067–2076. doi: 10.1016/S0140-6736(14)62225-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(14)62225-X</ArticleId>
            <ArticleId IdType="pubmed">25765696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, et al.  Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1:126–135. doi: 10.1001/jamacardio.2016.0103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamacardio.2016.0103</ArticleId>
            <ArticleId IdType="pubmed">27437883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaneko M, Narukawa M. Assessment of the risk of hospitalization for heart failure with dipeptidyl peptidase-4 inhibitors, saxagliptin, alogliptin, and sitagliptin in patients with type 2 diabetes, using an alternative measure to the hazard ratio. Ann Pharmacother. 2017;51:570–576. doi: 10.1177/1060028017698496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1060028017698496</ArticleId>
            <ArticleId IdType="pubmed">28622738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, et al.  A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374:1145–1154. doi: 10.1056/NEJMoa1506115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1506115</ArticleId>
            <ArticleId IdType="pubmed">27007958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, et al.  Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–383. doi: 10.2337/dc14-1142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc14-1142</ArticleId>
            <ArticleId IdType="pubmed">25352655</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
